[1]. Barbara Valsasina, et al. Novel thienoduocarmycin-trastuzumab ADC demonstrates Strong Anti-tumor Efficacy with Favorable Safety Profile in Preclinical Studies. Mol Cancer Ther. 2023 Sep 19.